Clinical Trial Update: Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the cystic fibrosis triple combination Elexacaftor/Tezacaftor/Ivacaftor in participants aged 12 to less than 24 months has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• TRIKAFTA (ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED